Bristol-Myers Squibb’s innovative cancer treatment Yervoy has been awarded the Prix Galien USA Discovery of the Decade biotech award.
The prize, awarded for the company’s recombinant human monoclonal antibody, also commemorated the tenth anniversary of the Prix Galien awards.
A scientific committee including several Nobel Laureates judged the awards.
Following its initial approval in 2012, Yervoy received the best biotechnology product award. It is now approved in over 50 countries for treatment of unresectable or metastatic melanoma.
Dr Francis Cuss, chief scientific officer and executive vice-president of research and development at Bristol-Myers Squibb, said: “We are honoured to receive this special recognition for Yervoy.”